Background. Cryptococcal meningitis (CM) remains a leading cause of acquired immunodeficiency syndromerelated death in sub-Saharan Africa. The timing of the initiation of antiretroviral therapy (ART) for human immunodeficiency virus (HIV)-associated CM remains uncertain. The study aimed to determine the optimal timing for initiation of ART in HIV-positive individuals with CM.
tifungal therapy, the mortality rate for CM is 100%. In sub-Saharan Africa, azoles are the primary therapy and have led to a reduction in short-term mortality rates, even though long-term outcomes remain poor [7] [8] [9] . Until recently, fluconazole monotherapy at dosages of 200-400 mg per day had been the standard of care in much of sub-Saharan Africa. Recent data suggest that higher doses (eg, 800-1200 mg per day) are safe, well tolerated, and more rapidly fungicidal than are lower doses [7, 10, 11] Amphotericin B with flucytosine results in improved outcomes, compared with azole monotherapy [12, 13] . In North America, the use of amphotericin B and flucytosine with aggressive management of elevated intracranial pressure has resulted in mortality rates of !10% [12, 14, 15] . In Africa, use of amphotericin B reduced the 14-day mortality rate to 17%-36% [3, [16] [17] [18] , but longterm follow-up of these participants has been limited. Because of its cost and the difficulty of administration and monitoring, amphotericin B and flucytosine are not routinely used in much of sub-Saharan Africa [19, 20] , and fluconazole currently remains the only option available for most patients. The drug is provided for free through the Pfizer Diflucan Partnership Program [21] .
The increased availability of antiretroviral therapy poses an opportunity to intervene and modify outcomes in individuals with HIV-associated opportunistic infections, such as CM. The timing of initiation of antiretroviral therapy (ART) in individuals with CM who are commencing antifungal therapy remains uncertain [22] . We conducted a prospective, open-label, randomized, 2-arm clinical trial to compare the 3-year mortality rates among participants allocated to receive early initiation of ART (р72 h after diagnosis of CM) or delayed initiation of ART (10 weeks after CM diagnosis). Study participants. Eligible participants were aged у18 years and HIV positive. HIV infection was determined using the national HIV testing protocol, by which HIV infection is documented by 2 positive results of different licensed rapid tests; in the event of a discordant result, a third rapid test is used as a tie breaker. All patients had CM confirmed by positive results of India ink identification of Cryptococcus neoformans in the cerebrospinal fluid (CSF) and/or a CSF cryptococcal polysaccharide antigen (CRAG) test (CALAS; Meridian Diagnostics). Participants were excluded if they had any of the following characteristics: patient had a previous diagnosis of or treatment for CM, was currently receiving ART, was receiving medications that affect the metabolism of fluconazole (especially rifampicin), was pregnant or lactating, or had a history of hepatic or renal dysfunction. To optimize retention and maximize follow-up, only participants who resided in a 50-km radius of Harare were enrolled.
METHODS

Study setting. The study was conducted at
Study design. A computer-generated randomization schedule was used to assign participants to the early ART and delayed ART arms of the study. This was an open-label study, and only the study statistician had access to the randomization schedule. The randomization sequence was concealed to the study nurse who was responsible for participant enrollment. After randomization assignment, physicians and nurses taking care of the participant were not blinded to the participant's treatment group.
All eligible participants were identified from the hospital's admission registry and microbiology laboratory, where CSF samples were processed. A chart review was performed for all patients in the adult medical wards who had CSF studies processed by the microbiology laboratory. Those whose India ink results were positive or whose chart review suggested meningitis (ie, the patient had headache, meningismus, fever, photophobia, and altered mental status) and met the eligibility criteria had CSF samples sent for CRAG testing. Participants whose CSF specimens yielded positive results of India ink examination and/or a CSF CRAG test were approached for recruitment, and informed consent was obtained in English or Shona (the local language) by the study nurse. Participants who could not consent for themselves or who did not have relatives available to consent for them were excluded. Consent had to be obtained р72 h after the diagnosis. At the time of enrollment, the next sequential enrollment number was allocated to the participant, and a sealed envelope bearing the corresponding number was opened by the participant to reveal the treatment group assignment. Baseline investigations included complete blood cell counts; CD4 cell counts; determination of electrolyte, urea, and creatinine levels; liver function tests; microscopic examination and culture of CSF samples; and CSF CRAG testing. Serum and CSF samples were stored for assessment of viral loads and CRAG titers, cultures, and future studies.
Treatment protocol. All participants were inpatients at the time of enrollment and started taking fluconazole (800 mg once per day; Diflucan [Pfizer] ) at the time of CM diagnosis. Participants were randomized to either initiate ART р72 h after diagnosis (the early ART arm) or to delay initiation of ART until after 10 weeks of fluconazole therapy (the delayed ART arm). Although participants were inpatients, they were treated by the primary medicine service, in accordance with the local standard of care; management included diagnostic lumbar punctures and measurement of CSF pressures, when manometers are available, but thereafter, CSF pressures are not monitored objectively. Worsening headaches and mental status may trigger repeated lumbar punctures.
After 10 Participants were observed at the Parirenyatwa Hospital outpatient HIV clinic at weeks 2, 4, 8, and 10. Thereafter, clinical evaluation was performed monthly, CD4 cell counts and complete blood cell counts were conducted every 3 months, and liver function tests were conducted every 6 months for up to 2 years. CSF was sampled at weeks 2, 4, and 10. CSF hypertension was reduced to !200 mm if it was found to be elevated at these visits or at any other visit necessitated by worsening headache. For patients who defaulted, telephone contacts and home visits were conducted.
The primary end point was all-cause mortality. Cause of death was ascertained through hospital records or contacts with next of kin if this occurred at home. Two investigators independently adjudicated and subsequently agreed on the cause of death.
Data safety and monitoring. On the basis of a number of factors, including feasibility and adequate statistical power, we chose a sample size per treatment arm of 100, for a total of 200 patients. This would provide adequate statistical power to be able to detect hazard ratios for the primary end point of mortality of at least 1.8.
An independent data safety monitoring committee was established with planned interim analysis after recruitment of 50% of participants. Initial estimated recruitment period was 24 weeks. However, recruitment was slow, and the first data safety monitoring committee review was conducted at 6 months when only 21 participants had been recruited. There were no safety or efficacy concerns, and the study was allowed to continue with enrollment. Recruitment continued to be slow, and the next data and safety review was conducted at 18 months, when 54 participants had been enrolled and all had commenced ART (either because they were in the immediate group or had reached week 10 after CM diagnosis). Analysis of the data showed a statistically significant difference in mortality between the 2 treatment groups, and it was decided to terminate study enrollment at that time.
Statistical analysis. All statistical analyses were based on the intention-to-treat principle. Baseline characteristics and mortality were compared between the 2 treatment arms. Continuous measures were summarized using means ‫ע(‬ standard deviations). Categorical variables were summarized using percentages. Differences between treatment arms were assessed using the x 2 test or the Fisher exact test for categorical variables and a 2-sample t test or Wilcoxon 2-sample t test for continuous variables. Equality of variances was assessed to determine the appropriate test.
For each patient, survival time was calculated as the time from randomization entry until death for those who died, and those who were alive were censored at the date of the last clinical encounter or on 31 October 2009. Participants that were lost to follow-up were censored at their last follow-up visit. The Kaplan-Meier plot and log-rank test were used to compare differences in mortality and the median time to death between the 2 treatment arms. Incidence rates and corresponding 95% confidence intervals (CIs) under Poisson distribution were also calculated. After confirming that the assumption of proportionality of hazards was met, we ran a Cox model to compare the risk of death in the 2 treatment arms while adjusting for baseline CD4 cell count, which was modelled as a continuous variable. All statistical analyses were performed using Stata software, version 10 (Stata Corp). A P value !.05 was considered to indicate statistical significance.
Ethics approval. The study was approved by the Joint Research Ethics Committee of the University of Zimbabwe College of Health Sciences and Parirenyatwa Central Hospital, the Medical Research Council of Zimbabwe, and the Medicines Control Authority of Zimbabwe.
RESULTS
A total of 1328 CSF samples were processed in the Parirenyatwa Central Hospital Microbiology Laboratory during the recruitment period. Four hundred eight had positive results of CRAG tests or India ink examinations, and 93 (23%) met eligibility criteria. Twenty-eight participants were randomized to the early treatment arm, and 26 were randomized to the delayed treatment arm (Figure 1) . The mean age of the participants was 37 ‫ע‬ 7.7 years, and 26 patients (48%) were women (Table 1) . Typical symptoms at presentation included chronic headache, with acute worsening of headache and associated mental status changes. Other common presenting symptoms included weight loss, fever, night sweats, and decreased cognitive function. There were no significant differences in baseline characteristics, presenting symptoms, and previous opportunistic infections between patients in the 2 treatment arms (Tables 1 and 2) .
The median CD4 cell count at enrollment was 37 cells/mm 3 (interquartile range, 17-69 cells/mm 3 ); there was no significant difference between the arms in the median CD4 cell count (P p .289) ( Table 1) . Baseline opening CSF pressures were not available for most participants, because the initial CSF opening pressures were done before study enrollment in the hospital's emergency department, where measurement of opening pressures was not routinely performed. All CSF samples tested negative for acid-and alcohol-fast bacilli by Ziehl-Neelsen staining.
The median duration of hospitalization was short, with most participants discharged from hospital within 1 week. Overall median follow-up time was 27 days (interquartile range, 9-571 days), with an overall 3-year mortality rate of 73%. The 3-year mortality rate was 88% in the early ART arm (n p 23) and 54% in the delayed ART arm (n p 12). Kaplan-Meier survival estimates for the 2 treatment groups revealed a median survival duration of 28 days (4 weeks) in the early ART arm and 637 days in the delayed ART arm (P p .031, by log-rank test) (Fig-Figure 1 . Study enrollment, treatment allocation, and analysis scheme. *Other included outpatients (n p 75), pregnant women (n p 1), patients with liver failure (n p 3), and persons enrolled in other studies (n p 16). ART, antiretroviral therapy; TB, tuberculosis. ure 2). Mortality typically occurred early in both treatment groups. Ten deaths (43.5%) in the early ART arm and 7 deaths (58.3%) in the delayed ART arm occurred р2 weeks after enrolment. Six participants died during the initial hospitalization (ie, they were never discharged from the hospital; 3 in each treatment group). Thirteen participants in the early ART arm and 1 in the delayed ART arm died during subsequent rehospitalizations. Fifteen participants died at home. Univariate analysis revealed that the only significant predictor of mortality was early ART initiation (P p .023). Low baseline CD4 cell count and CSF CRAG titer were not significant predictors of mortality (P p .067 and P p .72, respectively). The results of the unadjusted Cox model showed that early ART was associated with more than twice the risk of mortality, comparison with delayed ART (hazard ratio, 2.34; 95% CI, 1.12-4.89). After adjusting for the potential confounding effects of age, sex, CSF CRAG titer, and CD4 cell count, the hazard ratio increased (hazard ratio, 2.85; 95% CI, 1.1-7.23).
The mortality rate adjusted for age, sex, and CD4 cell count was 40 deaths per 1000 person-weeks at risk (95% CI, 2.6-60.9 deaths per 1000 person-weeks at risk) in the early ART arm, compared with 11 deaths per 1000 person-weeks at risk (95% CI, 6.1-19.9 deaths per 1000 person-weeks at risk) in the delayed ART arm (P ! .05). The cause of death for most participants was determined clinically at autopsy, and histopathological diagnoses were not available. The primary cause of death was CM in most patients (Table 3) .
DISCUSSION
We conducted a 2-arm randomized clinical trial to determine whether the timing of initiation of ART in participants with concurrent HIV infection and CM has an impact on survival. This study, to our knowledge, is the first prospective, randomized study to address whether the timing of initiation of ART has an impact on mortality in patients with advanced CM. Although other studies of mixed patient cohorts or nonrandomized studies have suggested that early ART treatment would decrease mortality and possibly improve clinical outcomes [22, 23] , the data from our study show that early ART results in increased mortality in individuals with HIV-associated CM.
In this study, mortality in both treatment groups was primarily due to complications related to CM, with most deaths occurring within the first 2 weeks after enrollment. Almost all deaths had occurred by week 4. The high mortality rates observed in this study are consistent with what has been observed in other studies and cohorts [8, 9] . However, the excess mortality associated with early initiation of ART suggest that early ART is detrimental in the treatment of patients with concurrent CM and HIV infection. Possible reasons for the detrimental effects of early ART in these participants include suboptimal Early introduction of nevirapine-based ART has been reported to result in adverse events, such as serious hepatotoxicity due to nevirapine-fluconazole drug interaction [24, 25] . Coadministration of fluconazole and nevirapine results in increased levels of nevirapine, with minimal effects on fluconazole drug levels [25] . The only nevirapine-related toxicity event observed in the study was a desquamating rash. Liver function test results remained normal throughout the study for participants in both treatment groups.
Early initiation of ART most likely resulted in increased rates of cryptococcal IRIS and the excess mortality observed in the early ART arm. However, in this study, we did not have objective criteria (eg, decreasing viral loads or increasing CD4 cell counts) to confirm IRIS. Suboptimal treatment of CM may increase the risk of CM IRIS, because the organism is cleared more slowly. The early initiation of ART may have altered central nervous system and peripheral cytokine profiles, thus limiting central nervous system clearance [26] . Dysregulation of the homeostatic balance in T cell subsets likely plays a role in the development of IRIS [27] [28] [29] . We postulate that early initiation of ART may have altered this balance resulting in a pro-inflammatory state that may have contributed to the significant increase in mortality in the early ART arm.
Our data provide strong evidence that, in the acute care setting, it is important to clear cryptococcal infection prior to initiation of ART. Early initiation of ART most likely resulted in increased rates of cryptococcal IRIS in the early ART arm. HIV-associated tuberculosis is yet another important opportunistic infection for which the timing of initiation of ART in relation to disease specific therapy remains incompletely answered. Data from an on-going South African study have shown that comparison of integrated (ART during tuberculosis therapy) versus sequential (ART following completion of tuberculosis therapy) resulted in a 55% lower mortality in the integrated treatment group [30] . We eagerly await results of the comparison of the 2 components of the integrated treatment group (early versus delayed ART), which best mirrors the comparison in our study. Our study had limitations, including the small sample size, the lack of blinding of clinicians to the randomization arm of the study, and the fact that the study was conducted in a setting where the overall management of CM is suboptimal. The study was nested in the routine standard of care in a tertiary care hospital in resource-limited circumstances. The researchers had no control over the general management of inpatients, including the measurement and management of elevated CSF pressures and the timing of discharge. Fluconazole drug susceptibility testing was also not performed in our study. Recent studies suggest a growing rate of resistance to fluconazole among cryptococcal isolates in Africa, prompting several clinicians to use increasingly higher doses of fluconazole [7, 31, 32] . Nonetheless, all but 2 participants who had survived until week 10 had negative India ink CSF staining and culture results at 10 weeks. Of the 2 participants who had not cleared their CSF of the organism, one was suspected to have developed tuberculosis-related IRIS, and the other-who had persistently positive CSF India ink and culture results-ultimately died of the disease several months after initiation of therapy. Despite these limitations, the data are highly applicable to the clinical setting prevalent in many resource-limited countries where the treatment of CM remains suboptimal.
Our study clearly shows that CM, when treated with fluconazole monotherapy (800 mg per day), does not favor early initiation of ART. We therefore recommend that, where fluconazole monotherapy is used for treating CM, initiation of ART should be delayed until the CM is adequately treated and, if possible, culture results are negative or titers have decreased significantly. On the basis of our data, outcomes are improved if treatment is initiated at least 10 weeks after initiation of treatment for CM.
